HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

wortmannin

inhibits PI3-kinase; inhibits alloantigen-specific T cell activation and cytotoxic T cell responses in human tumor cell lines

Also Known As:

MS 54; MS-54; (1 alpha,11 alpha)-11-(acetyloxy)-1-(methoxymethyl)-2-oxaandrosta-5,8-dieno(6,5,4-bc)furan- 3,7,17-trione

Networked: 362 relevant articles (12 outcomes, 21 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 52
- Steroids: 13904
  - Androstanes: 6
    - Androstenes: 4
      - Androstadienes: 1
        wortmannin: 362

Experts

1.	Chaudry, Irshad H: 6 articles (12/2009 - 06/2007)
2.	Bland, Kirby I: 6 articles (12/2009 - 06/2007)
3.	Schwacha, Martin G: 5 articles (12/2009 - 06/2007)
4.	Choudhry, Mashkoor A: 5 articles (08/2009 - 06/2007)
5.	Downey, James M: 4 articles (01/2010 - 02/2003)
6.	Cohen, Michael V: 4 articles (01/2010 - 02/2003)
7.	Hsieh, Chi-Hsun: 4 articles (12/2009 - 10/2007)
8.	Yang, Xi-Ming: 3 articles (01/2010 - 01/2005)
9.	Hsu, Jun-Te: 3 articles (12/2009 - 10/2007)
10.	Gao, Feng: 3 articles (09/2009 - 09/2007)

Related Diseases

1.	Neoplasms (Cancer) 07/07/2004 - "Among the ten most promising derivatives, six demonstrated lower liver toxicity and greater promise for inhibition of tumor cell growth than the lead structure wortmannin." 09/01/2007 - "The natural product, wortmannin, has been widely used to study the functional consequences of PI3K inhibition in both normal and transformed cells in culture but is not a suitable cancer chemotherapeutic agent due to stability and toxicity issues. " 05/01/2007 - "The objective of this study was to explore whether a specific inhibitor of PI3K, wortmannin, could potentiate the antitumor effect of radiation in vivo, particularly on radioresistant murine tumors. " 02/01/2001 - "Further studies are needed to compare the effects of wortmannin in human tumor cells and various normal cells including proliferative and quiescent cells." 12/01/2007 - "From the viewpoint of tumor control, including intratumor Q-cell control, wortmannin treatment in combination with gamma-ray irradiation is thought to be useful for suppressing the repair of radiation-induced damage." Order ALL the reference details at left...
2.	Ischemia 03/30/2001 - "Pretreatment of transgenic hearts with wortmannin immediately before and during ischemia eliminated reperfusion-mediated activation of Akt and neutralized the resistance to apoptosis. " 01/01/2009 - "PI3K/Akt inhibitor wortmannin (100 nM) was administered 15 min prior to 30-min regional (left anterior descending coronary artery occlusion) ischemia for the study of ischemic arrhythmias in the hearts perfused at constant coronary flow or prior to 30-min global ischemia followed by 2-h reperfusion for the infarct size (IS) determination (tetrazolium staining) in the hearts perfused at constant pressure. " 01/01/2008 - "RESULTS: Phosphorylation of PDK1(Ser241), GSK3-beta(Ser9) and PTEN(Ser380) was increased after ischemia/reperfusion in the mouse kidney, and phosphorylation of PDK1 was reduced by wortmannin administration. " 03/01/2007 - "Wortmannin (2 mg/kg, iv), a phosphoinositide 3-kinase inhibitor given 10 min before ischemia attenuated the beneficial effects of ischemic postconditioning. " 08/01/2006 - "Following groups were studied (n = 12 each group): IR, 30 min ischemia (I)/60 min Reperfusion (R); Post: 30 min ischemia, 6 circles of 10 s I/10 s R followed by 60 min R; Post Wort: 30 min ischemia, 6 circles of 10 s I/10 s R, wortmannin (10(-7) mol/L) followed by 60 min R; Wort: 30 min ischemia, wortmannin (10(-7) mol/L) followed by 60 min R. " Order ALL the reference details at left...
3.	Carcinoma (Carcinomatosis) 06/01/2003 - "Wortmannin radiosensitization was observed in Chinese hamster cells (V79-B310H , CHO-K1), mouse mammary carcinoma cells (SR-1), transformed human fibroblast (N2KYSV), chicken B lymphocyte wild-type cells (DT40), and chicken Rad54 knockout cells (Rad54-/-). " 08/01/2004 - "In this study, we show that TPCK inhibits TRAIL-induced caspase activity but potentiates wortmannin-dependent caspase activity in prostatic carcinoma cell lines. " 01/15/1998 - "This study examined the effects of wortmannin and protein kinase C (PKC) inhibitors on HGF-mediated changes in metabolic activity in glomerular mesangial cells and renal epithelial carcinoma A498 cells. " 05/15/2001 - "ET-743 was more effective in cells lacking DNA-PK; moreover, pre-treatment of HCT-116 colon carcinoma cells with wortmannin, a potent inhibitor of DNA-PK, sensitized cells to ET-743. " 09/15/1998 - "In this study, we demonstrate that AKT2 is activated in response to stimulation by insulin in a dose- and time-dependent manner in human ovarian carcinoma cells and that activation of AKT2 is abolished in cells pretreated with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase). " Order ALL the reference details at left...
4.	Hepatocellular Carcinoma (Hepatoma) 10/01/2007 - "Taken together, PI3K inhibitors LY294002 and wortmannin up-regulated beta1,4GT1 and enhanced CHX-induced apoptosis in SMMC-7721 cells, which suggested that PI3K inhibitors might have therapeutic potential when combined with CHX in the treatment of hepatoma." 11/01/1995 - "Wortmannin influences insulin regulation of gene 33 expression in rat hepatoma cells." 05/01/1995 - "Furthermore, wortmannin caused a significant reduction in insulin-stimulated DNA synthesis in Fao rat hepatoma cells. " 09/01/2006 - "METHODS AND RESULTS: SR-BI-dependent HDL selective cholesterol ester uptake in human HepG2 hepatoma cells was decreased (approximately 50%) by the PI3K inhibitors wortmannin and LY294002. " 01/01/2009 - "Wortmannin, a specific phosphatidylinositol kinase (PI3K) inhibitor that reverses the effect of HAb18G/CD147 on the regulation of intracellular Ca2+ mobilization, significantly reduced cell invasion potential and secretion of MMPs in human hepatoma cells (P < 0.05). " Order ALL the reference details at left...
5.	Anoxia (Hypoxia) 09/01/2007 - "They also confirm the role of mesothelial hypoxia in this model by the efficacy of the HIF inhibitor wortmannin." 01/01/2009 - "(4) Wortmannin resulted in decreased hypoxia-induced NO production and reduced activated eNOS levels. " 08/28/2008 - "The protective effect of HNG on infarct size was attenuated by wortmannin and Akti-1/2. Taken as a whole, these results suggest that PI3K/Akt activation mediates HNG's protective effect against hypoxia/ischemia reperfusion injury." 12/01/2009 - "The increase in Kupffer cell phagocytosis following hypoxemia was also prevented by Wortmannin or YC-1 treatment. " 06/07/2007 - "Additionally, overexpression of NF-kappaB partly reversed the ability of wortmannin to inhibit HIF-1alpha-dependent transcriptional activity, suggesting that NF-kappaB contributes to Akt-mediated HIF-1alpha accumulation during hypoxia. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
3.	1-Phosphatidylinositol 3-Kinase (PI 3 Kinase)
4.	Insulin (Novolin)
5.	Carbon Monoxide
6.	Cisplatin (Platino)
7.	Insulin-Like Growth Factor I (IGF-1)
8.	Antisense Oligonucleotides
9.	trabectedin (ecteinascidin 743)
10.	fluvastatin

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Aftercare (After-Treatment)
3.	Drug Therapy (Chemotherapy)
4.	Resuscitation
5.	Spinal Injections

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 20728 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>